Résultats de recherche pour « Biomanufacturing »

In biomanufacturing, developing an accurate model to simulate the complex dynamics of bioprocesses is an important yet challenging task. This is partially due to the uncertainty associated with bioprocesses, high data acquisition cost, and lack of data availability to learn complex relations in bioprocesses. To deal with these challenges, we propose to use a statistical machine learning approach, multi-fidelity Gaussian process, for process modelling in biomanufacturing. Gaussian process regression is a well-established technique based on probability theory which can naturally consider uncertainty in a dataset via Gaussian noise, and multi-fidelity techniques can make use of multiple sources of information with different levels of fidelity, thus suitable for bioprocess modeling with small data. We apply the multi-fidelity Gaussian process to solve two significant problems in biomanufacturing, bioreactor scale-up and knowledge transfer across cell lines, and demonstrate its efficacy on real-world datasets.

The development of continuous biomanufacturing processes requires robust and early anomaly detection, since even minor deviations can compromise yield and stability, leading to disruptions in scheduling, reduced weekly production, and diminished economic performance. These processes are inherently complex and exhibit non-linear dynamics with intricate relationships between process variables, thus making advanced methods for anomaly detection essential for efficient operation. In this work, we present a novel framework for unsupervised anomaly detection in continuous biomanufacturing based on an ensemble of generative adversarial networks (GANs). We first establish a benchmark dataset simulating both normal and anomalous operation regimes in a continuous process for the production of a small molecule. We then demonstrate the effectiveness of our GAN-based framework in detecting anomalies caused by sudden feedstock variability. Finally, we evaluate the impact of using a hybrid quantum/classical GAN approach with both a simulated quantum circuit and a real photonic quantum processor on anomaly detection performance. We find that the hybrid approach yields improved anomaly detection rates. Our work shows the potential of hybrid quantum/classical approaches for solving real-world problems in complex continuous biomanufacturing processes.

Biopharmaceutical manufacturing is vital to public health but lacks the agility for rapid, on-demand production of biotherapeutics due to the complexity and variability of bioprocesses. To overcome this, we introduce RApid PosTeriOR GENerator (RAPTOR-GEN), a mechanism-informed Bayesian learning framework designed to accelerate intelligent digital twin development from sparse and heterogeneous experimental data. This framework is built on a multi-scale probabilistic knowledge graph (pKG), formulated as a stochastic differential equation (SDE)-based foundational model that captures the nonlinear dynamics of bioprocesses. RAPTOR-GEN consists of two ingredients: (i) an interpretable metamodel integrating linear noise approximation (LNA) that exploits the structural information of bioprocessing mechanisms and a sequential learning strategy to fuse heterogeneous and sparse data, enabling inference of latent state variables and explicit approximation of the intractable likelihood function; and (ii) an efficient Bayesian posterior sampling method that utilizes Langevin diffusion (LD) to accelerate posterior exploration by exploiting the gradients of the derived likelihood. It generalizes the LNA approach to circumvent the challenge of step size selection, facilitating robust learning of mechanistic parameters with provable finite-sample performance guarantees. We develop a fast and robust RAPTOR-GEN algorithm with controllable error. Numerical experiments demonstrate its effectiveness in uncovering the underlying regulatory mechanisms of biomanufacturing processes.

The increasingly pressing demand of novel drugs (e.g., gene therapies for personalized cancer care, ever evolving vaccines) with unprecedented levels of personalization, has put a remarkable pressure on the traditionally long time required by the pharma R&D and manufacturing to go from design to production of new products. The revolution has already brought important changes in the technologies used within the industry. In fact, practitioners are increasingly moving away from the classical paradigm of large-scale batch production to continuous biomanufacturing with flexible and modular design, which is further supported by the recent technology advance in single-use equipment. In contrast to long design processes, low product variability (one-fits-all), and highly rigid systems, modern pharma players are answering the question: can we bring design and process control up to the speed that novel production technologies give us to quickly set up a flexible production run? In this tutorial, we present key challenges and potential solutions from the world of operations research that can support answering such question. We first present technical challenges and novel methods for the design of next generation drugs, followed by the process modeling and control approaches to successfully and efficiently manufacture them.

Biopharmaceutical manufacturing is a rapidly growing industry with impact in virtually all branches of medicines. Biomanufacturing processes require close monitoring and control, in the presence of complex bioprocess dynamics with many interdependent factors, as well as extremely limited data due to the high cost of experiments as well as the novelty of personalized bio-drugs. We develop a novel model-based reinforcement learning framework that can achieve human-level control in low-data environments. The model uses a dynamic Bayesian network to capture causal interdependencies between factors and predict how the effects of different inputs propagate through the pathways of the bioprocess mechanisms. This enables the design of process control policies that are both interpretable and robust against model risk. We present a computationally efficient, provably convergence stochastic gradient method for optimizing such policies. Validation is conducted on a realistic application with a multi-dimensional, continuous state variable.